A happy New Year 2018! We would like to greet the New Year with the familiar custom of our Welcome editorial, and Editors’ Choice articles, reflecting on an eventful year in 2017. Still marked in our hearts and minds, we celebrated the 60th anniversary of *Thrombosis and Haemostasis* in 2017! With around 900 submissions in 2017, we are happy and grateful that our authors and readers continue to keep us busy. We are delighted to report that our impact factor is now 5.627, corresponding to the steady growth of our journal’s profile and impact in the scientific community over the past 3 years.

We continue to serve as a link journal for the European Society of Cardiology Working Groups on Thrombosis and on Atherosclerosis and Vascular Biology, as well as being the official journal of the Spanish Society on Thrombosis and Haemostasis (SETH), the Gesellschaft für Thrombose- und Hämostaseforschung (GTH), and the Australian Vascular Biology Society (AVBS). Thrombosis and Haemostasis supports disseminating of important position documents, epitomizing the journal’s cutting edge information and consensus recommendations.

**Reviewers**

We offer lasting gratitude and great appreciation to our hardworking reviewers. Our ‘roll of honour’ of top -seven reviewers for 2017 includes the following experts:

- Job Harenberg
- Sam Schulman
- Cihan Ay
- Maria-Asuncion Esteve-Pastor
- Francesco Dentali
- Robert Storey
- Dirk Sibbing

Our sincere recognition goes to them, as well as to all other reviewers who have enthusiastically supported us in 2017. We are happy to announce that we count an annual average of 900 expert reviewers, providing reviews in a timely, highly competent and comprehensive manner.

We would like to remind you to update your ScholarOne profile regularly paying attention to ‘topics of interest’ and contact address changes. The ScholarOne database is regularly scanned for double accounts and incorrect e-mail addresses, which cause undelivered messages and useless loss of time by assigning reviewers. Please check the database before creating new accounts for invited referees to avoid double accounts. If you create an account for your co-author or a reviewer, be sure that the e-mail address is up to date. Please do not hesitate to contact Irina Moshkova or Elinor Switzer at the Editorial Office if you need any assistance.

**Section Editors**

We bid farewell to Marco Cattaneo (Italy), Frederick Ofosu (Canada), Wolfgang Siess (Germany), Meinrad Gawaz (Germany) and Johannes Oldenburg (Germany). We thank them for their help and support, and look forward to future collaborations and interactions with our alumni.

We also give a warm welcome to Tatjana Potpara, who joins us as a new Section Editor, with special responsibilities as Social Media editor. Our 60-year-old journal remains modern and dynamic, and social media profile, and upcoming forums and discussions are in planning. Watch this space!

A warm welcome is also extended to our new section editors, bringing new areas of interest and geographical coverage. We look forward to working together on our exciting journal.
**Final Thoughts ...**

We continue to optimize the effectiveness of the published theme issues through their citations, helping us to select topics and content. 'Thrombosis and Haemostasis' celebrated its 60th birthday with a very special and richly illustrated Anniversary issue (published in July 2017), providing a state-of-the-art view of past developments, current status and looking forward to future perspectives in the field of various topics of 'Thrombosis and Haemostasis'.

Starting with the January 2017 issue, 'Thrombosis and Haemostasis' presented a new and modernized cover design. The cover now varies each month, in harmony with the colours in the cover image. From 2018 on, there will be no colour indexing in the Table of Contents.

As alluded to, 'Thrombosis and Haemostasis' continues to stay active in digital sphere, inviting all interested to follow us for the latest news for our journal through the website: http://th.schattauer.de/en/home.html and social media.

With the move of Schattauer under the Thieme Publisher group, some changes have been introduced. You would also have noticed that 'Thrombosis and Haemostasis' now has only one volume per year with 12 issues making the numbering more straightforward to our readers. In 2017, it was volume 117 (issues 1–12).

Since this summer we also launched our open access offspring journal 'TH Open': https://www.thieme.de/de/th-open/journal-information.htm

This new journal is off to a great start, especially with its 'pay as you wish' Open Access model.

Finally, on behalf of the entire editorial staff including Dr. Elinor Switzer (Stuttgart), Irina Moshkova (Munich), Dr. Andrea Schürg (Publisher’s office in Stuttgart) and Thieme Publisher (Stuttgart), we would like to once again express our sincere thanks for your continued support, for active input and for enabling the many reviewing decisions during the last year, which have contributed toward maintaining the good reputation and impact of 'Thrombosis and Haemostasis' throughout this time.

We hope that the coming year will be a successful and productive one for you and your colleagues and look forward to continuing our work together in the future.

We remain with best wishes for a happy New Year 2018!

---

**References**

3. Lip GY, Weber C. May your New Year be happy and prosperous with "Thrombosis and Haemostasis". Thromb Haemost 2016;115:1–2

---

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
<th>Field of expertise</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geoff Barnes</td>
<td>United States</td>
<td>Venous thrombosis, pulmonary embolism, clinical trials: oral anticoagulants</td>
</tr>
<tr>
<td>Davide Capodanno</td>
<td>United States</td>
<td>Platelets, antithrombotics, coagulation</td>
</tr>
<tr>
<td>Christoph Binder</td>
<td>Austria</td>
<td>Atherosclerosis, autoantibodies, immunity, lipid mediators, microparticles</td>
</tr>
<tr>
<td>Yu Hu</td>
<td>China</td>
<td>Tissue factor/factor VII, coagulation factors, disseminated intravascular coagulation, gene targeting, gene therapy</td>
</tr>
<tr>
<td>Menno Huisman</td>
<td>The Netherlands</td>
<td>Clinical trials: fibrinolytic therapy, oral anticoagulants, heparins/LMW pulmonary embolism, deep vein thrombosis</td>
</tr>
<tr>
<td>Rory Koenen</td>
<td>The Netherlands</td>
<td>Arterial thrombosis, coagulation factors, chemokines, protein C/S pathway, adhesion molecules</td>
</tr>
<tr>
<td>Deirdre Lane</td>
<td>United Kingdom</td>
<td>Stroke/prevention, clinical trials: direct antithrombin agents, epidemiological studies, patient education, psychology</td>
</tr>
<tr>
<td>Lai-Heng Lee</td>
<td>Singapore</td>
<td>Acquired coagulation disorders, clinical studies, deep vein thrombosis, haemostasis, hypercoagulability</td>
</tr>
<tr>
<td>Tatjana Potpara</td>
<td>Serbia</td>
<td>Arterial thrombosis, cardiology, clinical trials: oral anticoagulants</td>
</tr>
<tr>
<td>Kathrin Schäfer</td>
<td>Germany</td>
<td>Atherosclerosis, cardiology, animal models, plasminogen activator inhibitors, vascular remodelling</td>
</tr>
</tbody>
</table>


